Company profile
AGIOS PHARMACEUTICALS, INC.
NASDAQ:AGIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AQVESME | approved | — | 1 | approved |
| PYRUKYND | approved | — | 1 | approved |
| MITAPIVAT | phase4 | — | 23 | active |
| IVOSIDENIB | phase1_2 | — | 3 | active |
| VORASIDENIB | phase1 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (47)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06924970 | phase2 | active_not_recruiting | 2025-05-01 | 2026-05-12 | Agios Pharmaceuticals, Inc. | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) |
| NCT05610657 | phase1 | completed | 2023-01-10 | 2023-07-21 | Agios Pharmaceuticals, Inc. | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function |
| NCT02108106 | phase1 | completed | 2014-03-01 | 2014-08-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT02149966 | phase1 | completed | 2014-05-01 | 2014-11-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT03960502 | phase1 | completed | 2019-05-16 | 2019-09-07 | Agios Pharmaceuticals, Inc. | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 216196 | 2022-02-17 | NDA | AGIOS PHARMACEUTICALS INC | |||||
Loading… | ||||||||